Pivotal Therapeutics Inc.

PVTTF

CA72582E1043

Pharmaceuticals

Delayed OTC Markets Other stock markets 04:17:54 2023-03-23 pm EDT			5-day change	1st Jan Change
0.0018 ^USD	+179,900.00%		-.--%	-.--%

2016	Pivotal Therapeutics Inc. Announces Management Changes	CI
2015	Ford Teams with Pivotal to Speed Development of Connected Car Experiences Capitalizing on New Ford Sync Connect	CI

Pivotal Therapeutics Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2014

August 27, 2014 at 03:21 pm EDT

Pivotal Therapeutics Inc. announced earnings results for the second quarter ended June 30, 2014. For the quarter, the company reported a loss of CAD 2,172,778, or CAD 0.02 per common share. In last year's second quarter, the loss was CAD 721,517 or CAD 0.01 per common share.

Latest news about Pivotal Therapeutics Inc.

Pivotal Therapeutics Inc. Announces Management Changes	16-05-06	CI
Ford Teams with Pivotal to Speed Development of Connected Car Experiences Capitalizing on New Ford Sync Connect	15-12-15	CI
Pivotal Therapeutics Inc. Executes International Distribution Agreement with Healthcore Co. Ltd	15-11-30	CI
Pivotal Therapeutics Inc. Announces Earnings Results for the Nine Months Ended September 30, 2015	15-11-30	CI
Pivotal Therapeutics Inc. announced that it has received CAD 0.1 million in funding	15-11-26	CI
Pivotal Therapeutics Inc. announced that it expects to receive CAD 1.58 million in funding	15-11-04	CI
Pivotal Therapeutics Inc. Announces Financial Results for the Six Months Ended June 30, 2015	15-08-29	CI
Pivotal Therapeutics Inc. cancelled the transaction announced on June 29, 2015	15-08-27	CI
Pivotal Therapeutics Inc. announced that it expects to receive CAD 1.54 million in funding	15-06-28	CI
Pivotal Therapeutics Inc. Announces the Enrollment of the First Patient in Pivotal's POMEGA Phase IIa Clinical Trial with PVT-100	15-06-04	CI
Pivotal Therapeutics Inc. Announces Audited Consolidated Earnings Results for the Three Months Ended March 31, 2015	15-06-02	CI
Pivotal Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2014	15-04-30	CI
Pivotal Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	15-04-29	CI
Pivotal Therapeutics Inc. Receives Health Canada Approval to Expand the Indication of Omazen	15-04-27	CI
Pivotal Therapeutics Inc. Executes Memorandum of Understanding for Distribution of Benefishial Line of Products in Korea	15-04-15	CI
Pivotal Therapeutics Inc. Receives Final Approval for Phase IIa Clinical Trial with PVT-100	15-01-27	CI
Pivotal Therapeutics Inc. Announces Earnings Results for the Three Months Ended September 30, 2014	14-11-28	CI
Pivotal Therapeutics Inc. Announces Resignation of Prakash Gowd as CFO	14-11-14	CI
Pivotal Therapeutics Inc. Announces Publication of Results of a Prospective Randomized Controlled Trial in the U.S	14-09-09	CI
Pivotal Therapeutics Inc. Announces Management Changes	14-09-08	CI
Pivotal Therapeutics Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2014	14-08-27	CI
Vmware, Inc. Announces Joint Initiatives with Docker, Google and Pivotal to Help Enterprises Run and Manage Container-Based Applications on a Common Platform	14-08-25	CI
Pivotal Therapeutics Inc. Reports Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2014	14-05-30	CI
Pivotal Therapeutics Inc. Announces Board Changes	14-05-13	CI
Pivotal Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	14-04-29	CI

Chart Pivotal Therapeutics Inc.

Duration

Period

More charts

Company Profile

Pivotal Therapeutics Inc is a Canada-based specialty pharmaceutical company with a focus on optimizing Omega-3 therapy for cardiovascular disease and overall health. The Company's lead product VASCAZEN is used to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase in high-density lipoprotein- Cholesterol (HDL-C) without a negative impact on the low density lipoprotein cholesterol (LDL-C) lipid profile. Its second product, OMAZEN is a greater than 90% pure, pharmaceutical grade Omega-3 commercialized for sale and distribution in Canada only for the maintenance of health.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
PIVOTAL THERAPEUTICS INC.	-.--%	172K
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.59%	44.15B
OTSUKA HOLDINGS CO., LTD.	+23.03%	23.02B
SANDOZ GROUP AG	+18.22%	15.33B
CIPLA LIMITED	+12.26%	13.74B
ZYDUS LIFESCIENCES LIMITED	+52.55%	12.16B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.88%	5.66B

Generic Pharmaceuticals